Gossamer Bio Inc

+0.06 (+0.47%)
Products, Earnings Announcements

Gossamer Bio Inc Announces Addition Of Two CNS-Penetrant BTK Inhibitors To Its Product Candidate Pipeline GB5121 & GB7208

Published: 10/11/2021 15:52 GMT
Gossamer Bio Inc (GOSS) - Gossamer Bio Announces Addition of Two Cns-penetrant Btk Inhibitors to Its Product Candidate Pipeline: Gb5121 & Gb7208.
Gossamer Bio - Plans to Initiate First-in-human Studies of First of These Candidates, Gb5121, in Q4 of 2021.
Gossamer Bio - Second Product Candidate, Gb7208, Currently in Ind-enabling Studies, Expected to Enter Clinic in H2 of 2022.
Gossamer Bio -intends to Develop Gb5121 in Cns-oncology Indications for Which Potentially Registrational Phase 1b/2 Study Expected to Begin in H1 2022.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.79

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.76

More details on our Analysts Page.